Dec 24 (Reuters) - Shares of Agios Pharmaceuticals (AGIO) jumped 18% on Wednesday after the U.S. Food and Drug Administration approved the expanded use of its drug for the treatment of a type of blood disorder.
The drug mitapivat is now approved as a treatment for patients with anemia in both non-transfusion-dependent and transfusion-dependent alpha- or beta-thalassemia, the company said late on Tuesday.
Thalassemia is an inherited blood disorder affecting the body's ability to produce hemoglobin and healthy red blood cells.
The drug, under the brand name Aqvesme, is expected to be available in late January next year, following the implementation of the required safety program.
Mitapivat was already approved by the U.S. FDA in 2022 to treat low red blood cell counts in adults with pyruvate kinase deficiency, under the brand name of Pyrukynd.
"The approval unlocks an additional $320 million in peak revenue opportunity layered atop the existing mitapivat franchise," Truist analyst Gregory Renza said.
The latest approval is based on a late-stage study in which patients receiving mitapivat showed a statistically significant increase in hemoglobin response compared to those on placebo.
Aqvesme will carry a boxed warning for liver function tests every four weeks during the first 24 weeks of treatment and advises against use in patients with cirrhosis, Renza added.
(Reporting by Siddhi Mahatole in Bengaluru; Editing by Vijay Kishore)
LATEST POSTS
- 1
James Webb Space Telescope spies mysterious high-energy radiation in star nursery - 2All the ways Marjorie Taylor Greene has shifted her approach lately — and why Trump is 'surprised at her'
- 3Defense Minister Katz finally condemns Jewish extremist violence against Palestinians
- 4Woman charged in unprovoked stabbing of tourist changing baby's diaper in Macy’s Herald Square store
- 54 injured in shooting at North Carolina tree lighting ceremony
- The most effective method to Move toward Compensation Conversations for Cutting edge Practice Enrolled Attendants
- The most effective method to Pick a Campervan That Offers Something else for Less
- Striking American and European television Projects: A Survey
- 'Seditious behavior': Trump accuses Democrats who made video reminding the military not to follow illegal orders of a crime — but is it?
- Full Supreme Court to hear challenge to Judicial Selection Committee law
- Go With The Breeze: Grand Paragliding Spots On the planet
- The Force of Positive Reasoning: Day to day Attestations
- From record warming to rusting rivers, 2025 Arctic Report Card shows a region transforming faster than expected
- Email Promoting Instruments for Compelling Efforts
